Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy

ABSTRACT Background Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VE...

Full description

Bibliographic Details

Published in:	eJHaem
Main Authors:	Rafael Madero‐Marroquin, Joseph Cannova, Emily Dworkin, Austin Wesevich, Gregory W. Roloff, Caner Saygin, Mariam T. Nawas, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Michael W. Drazer, Anand A. Patel
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Subjects:	acute leukemia AML chemotherapy MDS myeloid leukemia
Online Access:	https://doi.org/10.1002/jha2.70078